Savara Inc. (SVRA)
$4.76-0.42%Close
SELLRECOVERY · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $975M
- Beta
- 0.25
- P/E (TTM)
- -8.21
- Short % float
- 40.77%
- Days to cover
- 17.2
- SI change
- +0.5%
- 1W
- -2.46%
- 1M
- -9.51%
- vs SPY 1W
- -2.32%
- vs SPY 1M
- -12.01%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 8
- GROWTH
- 45
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-54.2%
REV YoY-
ROE-90.3%
EPS YoY-
ROA-72.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-8.21
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B8.40
P/FCF-
EV/EBITDA-6.93
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E20.96
ALTMAN Z-
CURR RATIO10.13
ND/EBITDA-
BETA0.25
Company news
FAQ
- What is LOPJLB’s current signal on SVRA?
- LOPJLB’s latest quantitative signal on Savara Inc. (SVRA) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is SVRA in?
- Savara Inc. (SVRA) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Savara Inc. (SVRA) do?
- Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main …